200 related articles for article (PubMed ID: 25997721)
1. [Orphan Drugs: Underrated Opportunities for The Developers in Europe].
Tillet Y; Maillols-Perroy AC
Therapie; 2015; 70(4):351-7. PubMed ID: 25997721
[TBL] [Abstract][Full Text] [Related]
2. [Orphan drugs: some legal, ethical and economics aspects].
Pabst JY
Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
[TBL] [Abstract][Full Text] [Related]
3. [European incentives for orphan medicinal products].
Enzmann H; Lütz J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
[TBL] [Abstract][Full Text] [Related]
4. The Orphan Drug Act. The first 7 years.
Asbury CH
JAMA; 1991 Feb; 265(7):893-7. PubMed ID: 1992188
[TBL] [Abstract][Full Text] [Related]
5. Understanding orphan drug regulations: an EU and U.S. comparative analysis.
Grienenberger A
J Biolaw Bus; 2004; 7(3):58-61. PubMed ID: 15460604
[TBL] [Abstract][Full Text] [Related]
6. New products highlight ambiguity of orphan drug law.
Reid B
Nat Biotechnol; 2003 Jan; 21(1):6-7. PubMed ID: 12511896
[No Abstract] [Full Text] [Related]
7. Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
Brabers AE; Moors EH; van Weely S; de Vrueh RL
Orphanet J Rare Dis; 2011 Sep; 6():59. PubMed ID: 21892964
[TBL] [Abstract][Full Text] [Related]
8. EMEA approves OGS drug rejected by FDA.
Mitchell P
Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
[No Abstract] [Full Text] [Related]
9. Navigating through orphan medicinal product regulations in EU and US--similarities and differences.
Tiwari J
Regul Toxicol Pharmacol; 2015 Feb; 71(1):63-7. PubMed ID: 25497996
[TBL] [Abstract][Full Text] [Related]
10. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
11. EU orphan regulation--ten years of application.
Michaux G
Food Drug Law J; 2010; 65(4):639-69, i-ii. PubMed ID: 24479246
[TBL] [Abstract][Full Text] [Related]
12. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
Wellman-Labadie O; Zhou Y
Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
[TBL] [Abstract][Full Text] [Related]
13. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform.
Clissold DB
Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989
[No Abstract] [Full Text] [Related]
14. Rare diseases and orphan drugs.
Taruscio D; Capozzoli F; Frank C
Ann Ist Super Sanita; 2011; 47(1):83-93. PubMed ID: 21430345
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceuticals. Adopt an orphan.
Karr A
Health Serv J; 1999 Nov; 109(5681):28. PubMed ID: 10724720
[No Abstract] [Full Text] [Related]
16. The challenges of orphan drugs and orphan diseases: real and imagined.
Hudson I; Breckenridge A
Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
[TBL] [Abstract][Full Text] [Related]
17. Do investors value the FDA orphan drug designation?
Miller KL
Orphanet J Rare Dis; 2017 Jun; 12(1):114. PubMed ID: 28629392
[TBL] [Abstract][Full Text] [Related]
18. Removal of the EMA orphan designation upon request of the sponsor: cui prodest?
Montanaro N; Bonaldo G; Motola D
Eur J Clin Pharmacol; 2021 Jul; 77(7):1057-1063. PubMed ID: 33501508
[TBL] [Abstract][Full Text] [Related]
19. [Orphan drugs].
Kolár J; Chalabala M; Srámková H
Ceska Slov Farm; 2001 Mar; 50(2):59-65. PubMed ID: 11288591
[TBL] [Abstract][Full Text] [Related]
20. Developing treatments for inborn errors: incentives available to the clinician.
Haffner ME
Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
